Country Reports

This report offers companies, investors, policymakers, and stakeholders crucial insight into Singapore; a nation that has had to carve out its own niche as a global trade hub and gateway to the Asia-Pacific region to compete globally since declaring independence in 1965. In terms of healthcare and life sciences, the island now serves as a…

This report offers companies, investors, policymakers, and stakeholders crucial insight into the Philippines; one of the most promising pharmaceutical markets in the Asia-Pacific region with a population of over 100 million, an annual GDP growth rate of around 6.5%, and a new administration committed to expanding healthcare access to all sections of the population. The…

This report offers companies, investors, policymakers, and stakeholders crucial insight into Luxembourg; a country that is rapidly breaking away from its reputation as simply a tiny European tax haven and establishing itself as a serious regional and global healthcare and life sciences player. Luxembourg has prioritized personalized healthcare; e-health and data security; and pharma logistics…

This report offers companies, investors, policymakers, and stakeholders crucial insight into Slovakia; a country with both political and economic stability; a Eurozone member that stands out in its region for being a member of the single currency; and, for the second half of 2016, has held the rotating presidency of the Council of the European…

This report offers companies, investors, policymakers, and stakeholders crucial insight into Switzerland; a country  located at the heart of Europe, home to some of the world’s most important international health institutions as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease…

This report offers companies, investors, policymakers, and stakeholders crucial insight into the Czech Republic; a country transforming itself from merely a producer of cheap generics to the regional headquarters of some of the largest pharmaceutical companies in the world. Located at the beating heart of Europe, boasting a highly-talented yet low-cost workforce, and with a…

The report features interviews with the global head of Ipsen, a representative of the IMS, and of the French pricing agency CEPS. Also included are interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the country’s healthcare and pharma sectors. It offers companies, investors, policymakers, and…

This report offers companies, investors, policymakers, and stakeholders crucial insight into Hungary; a country with more than 100 years of history in pharmaceuticals and a leading regional role in the industry. Regulatory reform post-2008 has seen Hungary weather the storm of economic recession and re-establish itself as a hub for world-class R&D, with a concentration…

This report offers companies, investors, policymakers, and stakeholders crucial insight into the birthplace of the modern pharmaceutical industry; a country that has transitioned out of economic recession and is now benefiting from its prime geographic position, tradition for quality manufacturing, and concentration of expertise. It also depicts how stakeholders are attempting to tackle the challenges…

The report features interviews with the global head of Ipsen, a representative of the IMS, and of the French pricing agency CEPS. Also included are interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the country’s healthcare and pharma sectors. It offers companies, investors, policymakers, and…

This report offers companies, investors, policymakers, and stakeholders crucial insight into the largest pharmaceutical manufacturing base and the second largest pharmaceuticals market by value in the Middle East. Despite recent political upheaval, Egypt is a key growth market with massive unmet needs and huge potential for potential investors.The report features a foreword from President Abdel…

This report is an authoritative assessment of the South African healthcare and pharma markets. It features an exclusive in-depth interview with Dr. Aaron Motsoaledi, South African Minister of Health, as well as with leading figures from both public institutions and private companies. Also included are up-to-date facts and figures on South Africa’s healthcare and pharma…